In the latest trading session, 0.52 million Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares changed hands as the company’s beta touched 1.28. With the company’s most recent per share price at $0.15 changed hands at -$0.02 or -7.60% at last look, the market valuation stands at $4.14M. SYRS’s current price is a discount, trading about -5206.67% off its 52-week high of $7.96. The share price had its 52-week low at $0.16, which suggests the last value was -6.67% down since then.
Analysts gave the Syros Pharmaceuticals Inc (SYRS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SYRS as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Syros Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.75.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Instantly SYRS was in red as seen in intraday trades today. With action -21.36%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -32.85%, with the 5-day performance at -21.36% in the red. However, in the 30-day time frame, Syros Pharmaceuticals Inc (NASDAQ:SYRS) is -26.98% down.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 97.0% from its recent market value. According to analyst projections, SYRS’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -3233.33% plunge from its current level, while the stock would need to soar -3233.33% for it to hit the projected low.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 386k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.16%. The 2025 estimates are for Syros Pharmaceuticals Inc earnings to increase by 72.84%, but the outlook for the next 5-year period is at 26.35% per year.
Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 654.18 shares estimated at $97604.0 under it, the former controlled 2.44% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.96% of the shares, roughly 257.63 shares worth around $38439.0.
